Table 3.
Association between treatment (HCQ-AZ vs. no HCQ-AZ) and six-week mortality, multivariate logistic regression (n = 16,063).
| aOR, 95% CIa | P | ||
|---|---|---|---|
| Sex (ref. Women) | Men | 1.71 1.05–2.78 | .0307 |
| Age (Ref. <50) | 50–69 | 12.14 2.43–60.62 | .0024 |
| >69b | 73.63 14.78–366.87 | <.0001 | |
| Period (Ref. 2020/03/03–2020/06/15) | 2021/03/22–2021/06/27 | 0.69 0.38–1.23 | .2089 |
| 2021/06/28–2021/09/21 | 1.34 0.69–2.60 | .3892 | |
| 2021/09/22–2021/12/31 | 0.88 0.42–1.84 | .7357 | |
| Outpatients (ref. No) | Yes | 0.11 0.07–0.18 | <.0001 |
| Vaccination (Ref. No) | Yes | 0.29 0.12–0.67 | .0041 |
| Obesity (Ref. No) | Yes | 2.01 1.23–3.29 | .0057 |
| High blood pressure (Ref. No) | Yes | 1.37 0.83–2.24 | .2150 |
| Asthma (Ref. No) | Yes | 0.76 0.26–2.23 | .6197 |
| Diabetes (Ref. No) | Yes | 1.32 0.77–2.27 | .3145 |
| Autoimmune diseases (Ref. No) | Yes | 0.69 0.23–2.05 | .5043 |
| Cancer (Ref. No) | Yes | 1.34 0.65–2.74 | .4278 |
| Chronic cardiac disease (Ref. No) | Yes | 1.20 0.60–2.41 | .6098 |
| Immunodeficiency (Ref. No) | Yes | 4.01 1.69–9.50 | .0016 |
| COPD (Ref. No) | Yes | 2.93 1.29–6.64 | .0100 |
| Treatment (ref. No HCQ-AZc (n = 3115)) | HCQ-AZc (n = 12,945) | 0.47 0.29–0.76 | .0020 |
This subgroup was mainly composed of outpatients (95%) included only in 2021. Five percent of inpatients were patients who presented at our day hospital and were directly hospitalized the same day.
a
Adjusted odds ratio with 95% confidence interval.
b
The “>89” age group (n = 55) was merged with the “70–89” age group.
c
HCQ: Hydroxychloroquine, AZ: Azithromycin, IVM: Ivermectin.